tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
CytomX Therapeutics price target raised to $8 from $6 at Barclays
PremiumThe FlyCytomX Therapeutics price target raised to $8 from $6 at Barclays
2M ago
CytomX Therapeutics: Asymmetric Upside Ahead of Pivotal CX-2051 Colorectal Cancer Data Supports Reiterated Buy and $10 Target
Premium
Ratings
CytomX Therapeutics: Asymmetric Upside Ahead of Pivotal CX-2051 Colorectal Cancer Data Supports Reiterated Buy and $10 Target
2M ago
CytomX Therapeutics announces business update, 2026 milestones
Premium
The Fly
CytomX Therapeutics announces business update, 2026 milestones
2M ago
CytomX Therapeutics Reports Q3 2025 Financial Results
PremiumCompany AnnouncementsCytomX Therapeutics Reports Q3 2025 Financial Results
4M ago
CytomX Therapeutics reports Q3 EPS (9c), consensus (4c)
Premium
The Fly
CytomX Therapeutics reports Q3 EPS (9c), consensus (4c)
4M ago
CytomX Therapeutics Advances CX-2051 Study in Solid Tumors
Premium
Company Announcements
CytomX Therapeutics Advances CX-2051 Study in Solid Tumors
4M ago
Oppenheimer positive on CytomX after Merus colon cancer data
PremiumThe FlyOppenheimer positive on CytomX after Merus colon cancer data
5M ago
CytomX Therapeutics: Hold Rating Amid Awaited CX-801 Data and Market Potential
Premium
Ratings
CytomX Therapeutics: Hold Rating Amid Awaited CX-801 Data and Market Potential
5M ago
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100